Lesamor

Telmisartan/Hydrochlorothiazide, the active ingredient in Lesamor, is an angiotensin II receptor blocker/thiazide diuretic presented as a tablet for oral use. It is indicated for the treatment of hypertension in adult patients.

GNH USA supplies Lesamor as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lesamor (telmisartan/hydrochlorothiazide) is used to manage high blood pressure by targeting the renin‑angiotensin system and promoting diuresis.

- Hypertension: lowers systolic and diastolic blood pressure in adults, helping to reduce the risk of cardiovascular complications.

Adverse reactions may occur with Lesamor and are categorized by frequency.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Increased urinary frequency - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal upset

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance - Acute kidney injury or worsening renal function - Hyperkalemia - Angioedema or severe allergic reaction - Marked hypotension - Hepatic dysfunction

Before initiating therapy, clinicians should consider several safety aspects. - Blood pressure monitoring: ensure adequate control and avoid excessive hypotension. - Renal function assessment: evaluate serum creatinine and eGFR, especially in patients with pre‑existing kidney disease. - Electrolyte surveillance: monitor potassium and sodium levels regularly. - Hepatic impairment: use with caution in patients with liver disease. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Lesamor may interact with other medicines, requiring attention to the interaction strength.

Major Interactions (Avoid): - Aliskiren (in patients with diabetes or renal impairment) - Potassium‑sparing diuretics or supplements (risk of hyperkalemia) - Lithium (increased lithium toxicity) - ACE inhibitors or other ARBs (excessive renin‑angiotensin blockade) - NSAIDs (may reduce antihypertensive effect and impair renal function)

Moderate Interactions (Monitor Closely): - Other antihypertensive agents (additive blood‑pressure lowering) - CYP3A4 inhibitors (e.g., ketoconazole, may increase telmisartan levels) - Diuretics (enhanced electrolyte loss) - Antidiabetic drugs (possible alteration of glucose control)